Ticker Launch

SPAC · Merger completed

Helix Acquisition Corp. II

Business combination with TheRas, Inc.

Helix Acquisition Corp. II is a blank-check company (SPAC) that raised $160M in its initial public offering on Feb 13, 2024, listing on Nasdaq. It completed its business combination with TheRas, Inc. on Aug 11, 2025; the combined company is BridgeBio Oncology Therapeutics, Inc. (BBOT). White & Case advised the SPAC and Kirkland & Ellis advised the underwriters on the IPO.

Status
Merger completed
IPO date
Feb 13, 2024
IPO size
$160M
IPO exchange
Nasdaq
Target
TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics)
Announced
Mar 3, 2025
Closed
Aug 11, 2025
Combined company
BridgeBio Oncology Therapeutics, Inc. (BBOT)
SPAC counsel (IPO)
White & Case and Maples and Calder
Underwriters' counsel (IPO)
Kirkland & Ellis

More on this SPAC for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Then $99/month or $999/year. Cancel anytime.

Filings

Other deSPACs that closed in 2025